A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Enzalutamide
Related studies linked through entity extraction aliases.
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Status
- RECRUITING
- Phase
- PHASE3
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- Status
- RECRUITING
- Phase
- PHASE3
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Status
- RECRUITING
- Phase
- PHASE2
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
- Status
- COMPLETED
- Phase
- N/A
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Status
- RECRUITING
- Phase
- PHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2